Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1991 Oct;344(4):449-53.
doi: 10.1007/BF00172585.

Effects of clenbuterol, ICI118551 and sotalol on the growth of cardiac and skeletal muscle and on beta 2-adrenoceptor density in female rats

Affiliations

Effects of clenbuterol, ICI118551 and sotalol on the growth of cardiac and skeletal muscle and on beta 2-adrenoceptor density in female rats

M N Sillence et al. Naunyn Schmiedebergs Arch Pharmacol. 1991 Oct.

Abstract

The aim of the present study was to determine whether the anabolic effects of clenbuterol in rat skeletal muscle are mediated by beta 2-adrenoceptor stimulation. Female rats were treated with clenbuterol, alone or in combination with either the nonselective beta 1/beta 2-adrenoceptor antagonist sotalol, or the beta 2-adrenoceptor-selective antagonist ICI118551. Clenbuterol caused an increase in muscle growth, accompanied by a reduction in beta 2-adrenoceptor density in the rat hind-limb. Both actions were attenuated by sotalol. However, at the dose tested ICI118551 was the more effective antagonist of the muscle growth response, and when given alone, ICI118551 caused significant muscle atrophy. An increase in the weight of the heart was also observed in clenbuterol-treated rats, and again while this effect was attenuated by sotalol, it was reversed by ICI118551. It is concluded that beta 2-adrenoceptors mediate the anabolic effects of clenbuterol in cardiac and skeletal muscle, and that they play an important physiological role in the growth and maintenance of muscle mass in the rat hind-limb.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Lancet. 1990 Dec 8;336(8728):1411-2 - PubMed
    1. J Pharmacol Exp Ther. 1971 Feb;176(2):302-11 - PubMed
    1. Arzneimittelforschung. 1972 May;22(5):869-76 - PubMed
    1. Naunyn Schmiedebergs Arch Pharmacol. 1991 Oct;344(4):442-8 - PubMed
    1. J Biol Chem. 1979 Jan 25;254(2):530-9 - PubMed

Publication types

MeSH terms